Pemphigus Vulgaris: Present and Future Therapeutic Strategies

Dermatology Practical & Conceptual

Riccardo Pampena¹  Dario Didona²  Giovanni Di Zenzo³  Biagio Didona³  Matteo Riccardo Di Nicola⁴  Santo Raffaele Mercuri⁴  Giovanni Paolino⁴ 

[1] Centro Oncologico ad Alta Tecnologia Diagnostica-Dermatologica, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Italy;Department of Dermatology and Allergology, Philipps University, Marburg, Germany;IDI-IRCCS, Rome, Italy;Unit of Dermatology, IRCCS San Raffaele Hospital, Milan, Italy;

关键词: anti-CD20 antibodies;    neonatal Fc receptor (FcRn);    pemphigus;    rituximab;    treatment;   

DOI  :  10.5826/dpc.1201a37

来源: DOAJ

【 摘 要 】

Pemphigus vulgaris (PV) belongs to the group of autoimmune blistering diseases. PV can affect not only mucous membranes, but also the skin and it is characterized by serum IgG autoantibodies against desmoglein 1 and 3, two major components of desmosomes. The introduction of glucocorticoids improved dramatically the prognosis of patients affected by PV.  However, long-term use of high dose corticosteroids and adjuvant steroid-sparing immunosuppressants can lead to several adverse events. Rituximab, a chimeric anti-CD20 monoclonal antibody, has been recently approved as in-label therapy for PV, leading to an improvement of the prognosis and higher remission rate. Furthermore, other anti B-cell therapies and several anti-CD20 biosimilars have been introduced in the clinical practice. We focused on present and future therapeutic approaches in PV

【 授权许可】

Unknown